Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.48 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.47 |
| ▸ | CTRL | P40313 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.47 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.47 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.47 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84970 | 0.91 | CAPN1 (0.50) | CAPN1CTSLPSMB5CAPN2ACE | |
| SCHEMBL92790 | 0.90 | PSMB5 (0.52) | PSMB5TMPRSS11DCTRLCTSBPSMB11 | |
| SCHEMBL2633243 | 0.89 | PSMB5 (0.52) | PSMB5ACETMPRSS11DCTRLCTSB | |
| SCHEMBL14447096 | 0.87 | BIRC2 (0.53) | CAPN1PSMB5IL1RNERAP2TMPRSS11D | |
| SCHEMBL2605636 | 0.83 | BIRC2 (0.55) | CAPN1PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL9642170 | 0.83 | PSMB5 (0.56) | PSMB5 | |
| SCHEMBL8267211 | 0.83 | TMPRSS11D (0.47) | CAPN1PSMB5TMPRSS11DCTRLCTSB | |
| SCHEMBL21261810 | 0.82 | CAPN1 (0.57) | CAPN1CTSLIL1RNERAP2ERAP1 | |
| SCHEMBL21261667 | 0.82 | CAPN1 (0.57) | CAPN1CTSLIL1RNERAP2ERAP1 | |
| SCHEMBL23616279 | 0.82 | CTSL (0.55) | CAPN1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CAPN1 276/4885CTSL 203/4885PSMB5 24/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | CAPN1 242/4885CTSL 177/4885PSMB5 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.